Heba El Goweni, M.D. Pediatrics - Adolescent Medicine Medicare: Not Enrolled in Medicare Practice Location: 8880 Navarre Pkwy, Suite 102, Navarre, FL 32566 Phone: 850-939-5550 Fax: 850-939-5445 |
Dr. Jennifer C Allen Johnson, M.D. Pediatrics - Adolescent Medicine Medicare: Not Enrolled in Medicare Practice Location: 8990 Navarre Parkway, Pediatric Department, Navarre, FL 32566 Phone: 850-396-0108 Fax: 850-939-4933 |
Dr. Alison Stotts Curtsinger, M.D Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 7295 Navarre Pkwy, Navarre, FL 32566 Phone: 850-898-0149 Fax: 833-913-2541 |
Omaima Mousa, M.D. Pediatrics - Adolescent Medicine Medicare: Not Enrolled in Medicare Practice Location: 8880 Navarre Pkwy Ste 102, Navarre, FL 32566 Phone: 850-939-5550 Fax: 850-939-5445 |
Dr. Melanie V Parm, D.O Pediatrics Medicare: Medicare Enrolled Practice Location: 8990 Navarre Pkwy, Navarre, FL 32566 Phone: 850-396-0108 Fax: 850-939-4933 |
News Archive
A report issued by Thomson Reuters and shared in part at the Aspen Ideas Festival on July 10th, indicates that a combination of better coordinated public and private sector care; stronger patient awareness of health risks and wellness; and application of improved information systems to eliminate fraud and abuse could lead to a 50% reduction in wasteful spending in healthcare, saving 3.6 trillion dollars over the next decade.
A commonplace electroencephalography (EEG) test may hold the key to predicting whether a person will respond to certain prescribed drugs, particularly those related to psychiatric conditions.In a study to be published by Clinical Neurophysiology, and now posted online, engineering and health sciences researchers at McMaster University applied machine learning to EEG patterns and successfully predicted how patients with schizophrenia would respond to clozapine therapy.
Mana Health's ManaPortal version 1.0.0, has achieved ONC HIT 2014 Edition Modular EHR certification, which designates that the software is capable of supporting eligible providers and hospitals with meeting the Stage 1 and Stage 2 Meaningful Use measures required to qualify for funding under the American Recovery and Reinvestment Act.
TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced presentations of new data on its Smac mimetic drug candidate TL32711 at the 2011 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics in San Francisco.
Cutting edge research in basic cardiovascular science will be presented at Frontiers in CardioVascular Biology (FCVB) 2014, held 4-6 July at the Palau de Congressos de Catalunya in Barcelona, Spain.
› Verified 7 days ago